Simone Seiter
Director/Board Member chez GENSIGHT BIOLOGICS S.A.
Profil
Simone Seiter is the founder of Priothera SAS.
He currently holds two positions, Independent Director at Gensight Biologics SA since 2017 and Senior Partner at Simon-Kucher & Partners, Inc. since 2020.
Previously, he worked at IQVIA as Vice President from 2006 to 2019.
Dr. Seiter has a graduate and doctorate degree from Ruprecht-Karls-Universität Heidelberg and an MBA from the University of Applied Sciences Fh Rendsburg.
Postes actifs de Simone Seiter
| Sociétés | Poste | Début |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Director/Board Member | 19/04/2017 |
| Simon-Kucher & Partners, Inc. | Corporate Officer/Principal | 01/01/2020 |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Founder | - |
Anciens postes connus de Simone Seiter
| Sociétés | Poste | Fin |
|---|---|---|
| IQVIA | Corporate Officer/Principal | 01/01/2019 |
Formation de Simone Seiter
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| University of Applied Sciences Fh Rendsburg | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| IQVIA | |
| Simon-Kucher & Partners, Inc. | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The private company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Health Technology |
